Safety: Clinical Trials

11 trials for Safety, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 unknown. 11 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Unknown 11
Phase 14Unknown 4
Phase 32Unknown 2

Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
Tirolizumab+SOX/XELOX, SOX/XELOX - Locally Advanced Gastric Carcinoma, HER2 Negative
Phase 2UnknownLin Chen802023-10-012024-02-29
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
Cadonilimab, Stereotactic body radiotherapy - Advanced Solid Tumor, Stereotactic Body Radiotherapy
Phase 1 / Phase 2UnknownPeking University Third Hospital602023-06-212023-06-23
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2; - Immunogenicity, Safety
Phase 2 / Phase 3UnknownStemirna Therapeutics8002023-06-202023-06-20
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease
Phase 2UnknownShanghai General Hospital, Shanghai Jiao Tong University School of Medicine302023-01-102023-06-28
A Phase Ic/IIb Study to Evaluate the Efficacy,Safety and Pharmacokinetics of HST in Patients With CHB
Hepenofovir Fumarate Tablets - Efficacy, Safety
Phase 1 / Phase 2UnknownXi'an Xintong Pharmaceutical Research Co.,Ltd.482022-11-102023-11-08
PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer
PD-L1 inhibitor - Efficacy, Safety
Phase 1 / Phase 2UnknownThe Affiliated Hospital of Qingdao University302022-04-012022-04-13
Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients
Advixa (Adalimumab) - Pharmacokinetics, Safety
Phase 2 / Phase 3UnknownInstitute for Developing Science and Health Initiatives, Bangladesh2002021-06-022022-07-07
Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance
Almonertinib combine with Pyrrolitinib - Safety
Phase 2UnknownSun Yat-sen University362020-12-312021-03-08
Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC
Tislelizumab 200 mg, Carboplatin AUC 5, pemetrexed 500mg/m2 - Tislelizumab, Safety
Phase 2UnknownHao Long1002020-12-222022-02-17
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19
Nintedanib 150 MG, Placebo - COVID-19, Nintedanib
Phase 2UnknownHuilan Zhang962020-04-022020-04-08
Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients
Umbilical cord blood infusion, Erythropoietin injection, Placebo umbilical cord blood infusion - Stroke, Umbilical Cord Blood
Phase 1 / Phase 2UnknownBundang CHA Hospital242019-05-022020-11-05

Narrower conditions

Arthritis, Rheumatoid (1)  ·  COVID-19 (1)  ·  Diabetes Mellitus, Insulin-Dependent, 12 (1)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)  ·  Stroke (1)

Broader conditions

Immune System Diseases (2)  ·  Arthritis (1)  ·  Autoimmune Diseases (1)  ·  Brain Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Connective Tissue Diseases (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Infections (1)

Interventions

130-nm albumin-bound paclitaxel (1)  ·  Adalimumab (1)  ·  Carboplatin (1)  ·  Erythropoietin (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Paclitaxel (1)  ·  Pemetrexed (1)  ·  Radiosurgery (1)  ·  Rehabilitation (1)  ·  nintedanib (1)  ·  tislelizumab (1)

Sponsors

Bundang CHA Hospital (1)  ·  Hao Long (1)  ·  Huilan Zhang (1)  ·  Institute for Developing Science and Health Initiatives, Bangladesh (1)  ·  Lin Chen (1)  ·  Peking University Third Hospital (1)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)  ·  Stemirna Therapeutics (1)  ·  Sun Yat-sen University (1)  ·  The Affiliated Hospital of Qingdao University (1)  ·  Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1)

Countries

China (6)  ·  Bangladesh (1)  ·  South Korea (1)

Top investigators

Hongqing Zhuang, M.D. (1)  ·  Mayfong Mayxay, doctor (1)  ·  MinYoung Kim, MD,PhD (1)  ·  Xianmin G Song (1)  ·  Xiaochun Zhang, Prof (1)  ·  Zannat Kawser, M.Phil. (1)

Results publications

PMID 33538338, PMID 40693391, PMID 41456040, PMID 41499358